12:00 AM
 | 
Nov 19, 2007
 |  BioCentury  |  Strategy

The disappointments

The disappointments

Year Compound Indication Setback
2007 Bifeprunox Schizophrenia Partners Wyeth and Solvay received a not approvable letter from FDA in response to an NDA for bifeprunox for the acute treatment of...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >